Despite available treatment, there is still significant morbidity and mortality present among patients with the autoimmune thrombophilic condition termed 'antiphospholipid syndrome' (Espinosa, G. and Cervera, R. 2009. Morbidity and mortality in the antiphospholipid syndrome. Curr. Opin. Pulm. Med. 15:413.). High-avidity (HAv) anti-b 2 -glycoprotein I (anti-b 2 GPI) antibodies, shown to correlate with thrombotic events in patients, could represent the much needed improved prognostic marker. By studying their effect on crystalline annexin A5 shield on phospholipid surfaces (one of proposed pathogenic mechanisms), with the use of atomic force microscopy, the pathogenic potential of HAv anti-b 2 GPI antibodies was confirmed. Furthermore, by using surface plasmon resonance and enzymelinked immunosorbent assays, unique binding characteristics of HAv antibodies in comparison with low avidity antibodies were established. HAv anti-b 2 GPI were confirmed to (i) recognize b 2glycoprotein I in a solution, (ii) interact predominantly monovalently (much lower dependency on the antigen density) and (iii) form more stable complexes with the antigen. Since enzyme-linked immunosorbent assays currently used in routine diagnostics detect anti-b 2 GPI antibodies of unknown avidity, our observations are potentially useful for the development of improved diagnostic tests capable of detecting clinically relevant antibodies.
Introduction
Anti-b 2 -glycoprotein I (anti-b 2 GPI) antibodies as one of the hallmarks of the antiphospholipid syndrome (APS) significantly correlate with thrombosis and recurrent pregnancy loss (1) (2) (3) (4) . However, not all patients with elevated anti-b 2 GPI show clinical symptoms. This could be explained by heterogeneity of anti-b 2 GPI regarding their epitope specificity and their avidity. Such diversity is well expected for an in vivo B-cell response, reflected in the production of the anti-b 2 GPI of different avidity and the location and nature of epitopes recognized on b 2 -glycoprotein I (b 2 GPI) (5) (6) (7) . Heterogeneity of anti-b 2 GPI in regard to their avidity has been confirmed by chaotropic ELISA (8, 9) . Clinical significance of autoantibodies' avidity has been addressed many times and is still the subject of the ongoing studies. Even 15 years ago, Gharavi and Reiber (10) suggested that high-avidity (HAv) autoantibodies could play a critical role in organ-specific autoimmune disorders, whereas in immune complex-mediated disorders, HAv and low-avidity (LAv) antibodies might be equally pathogenic. Vlachoyiannopoulos et al. (9) showed that APS-associated anti-b 2 GPI usually exhibit high urea resistance, which is compatible with HAv, while LAv anti-b 2 GPI are present in non-APS individuals. According to Reddel and Krilis (11) , APS does not appear to be a uniform predilection to thrombosis but, rather, a spectrum of severity that may depend on many factors including antiphospholipid antibodies' avidity. The tendency of HAv anti-b 2 GPI in APS patients to be associated with thrombosis has been subsequently reported (8, 12, 13) . According to de Laat et al. (14) , pathologic anti-b 2 GPI can be divided into those targeting epitope on domain I (directed against the G40-R43 residues) which highly correlate with thrombosis, and those targeting non-domain I epitopes. Giannakopoulos et al. (15) hypothesized that these differences are due to anti-b 2 GPI avidity.
Many mechanisms have been proposed to explain the pathogenic function of anti-b 2 GPI, one of them being the increased resistance to annexin A5 (ANX A5) (16) (17) (18) (19) . The anticoagulant properties of ANX A5 are a consequence of ANX A5 crystallization on phospholipid membranes, resulting in a protein lattice over phospholipid surfaces (20) -hindered phospholipid surfaces are blocked and consequently unavailable for coagulation reactions. Recently, Irman et al. (21, 22) reported that APS patients-derived antibodies (anti-b 2 GPI and anti-ANX A5) interfere with the formation of the ANX A5 shield on phospholipid bilayers which was suggested to accelerate phospholipid-dependent coagulation reactions (23, 24) .
Together with the fact that anti-b 2 GPI avidity is a rather stable parameter in an individual patient (25) , the presence of HAv anti-b 2 GPI could very well be considered as a (specific) prognostic marker. Therefore, the aim of the present work was (i) to compare the binding of HAv and LAv polyclonal anti-b 2 GPI to b 2 GPI under various conditions and (ii) to visualize the pathogenic relevance of HAv anti-b 2 GPI on the ANX A5 anticoagulant shield on an in vitro model of solidsupported phospholipid bilayers (SPBs). For this purpose, we affinity separated anti-b 2 GPI of each individual patient by gradient salt (ionic strength) elution and obtained two antib 2 GPI fractions: one predominately containing LAv anti-b 2 GPI and the other predominately containing HAv anti-b 2 GPI.
Methods

Serum samples
Sera of 30 patients with APS and/or systemic lupus erythematosus, positive for anti-b 2 GPI IgG, were selected from the sera bank of the Department of Rheumatology, University Medical Centre, Ljubljana, Slovenia. Avidity of anti-b 2 GPI IgG was determined using chaotropic ELISA. Two sera were selected based on their avidity, titer and volume availability for the purification of antibodies. Both sera were from patients with primary APS, who suffered initially from venous thrombosis and were positive for IgG anticardiolipin antibodies and IgG anti-b 2 GPI. IgG fraction of serum A (sample A) predominately contained HAv anti-b 2 GPI. At the time of serum collection, the patient had overt thrombotic manifestation, namely a central nervous system and skin microthromboses, diagnosed as catastrophic APS which later on resulted in the patient's death. IgG fraction of serum B (sample B) contained anti-b 2 GPI of heterogeneous avidity. At the time of serum collection, the patient was symptom free regarding APS and had the only thrombotic manifestation several years ago. Two healthy donors' sera without antiphospholipid antibodies (designated C and D) were also selected as negative controls. As positive control, a human chimeric IgG monoclonal anti-b 2 GPI antibody (HCAL) (26) was used (Inova Diagnostics Inc., San Diego, CA, USA). The study was approved by the Ethics' Committee of the Slovenian Ministry of Health.
Avidity determination of anti-b 2 GPI by chaotropic ELISA Avidity of anti-b 2 GPI was determined by introducing chaotropic conditions in the anti-b 2 GPI ELISA during the antibodybinding phase. Sera, sample A and sample B were diluted in PBS, pH 7.4, with 0.05% Tween 20 (0.05% PBST) containing increasing concentrations of NaCl (0.15, 0.25, 0.5, 1, 2 and 4 M) and applied to b 2 GPI-coated microtiter plates (High Binding; Costar, Cambridge, MA, USA). The detection system was the same as in the anti-b 2 GPI ELISA. Samples in which 70% of the initial binding (at 0.15 M NaCl) was preserved at 0.5 M NaCl were declared as HAv, samples in which the initial binding decreased to and below 25% were declared as LAv, and the samples in between the criteria were declared heterogeneous (8) . Sample A was declared as predominantly HAv with 91% of initial binding and sample B as heterogeneous avidity with 46% of initial binding.
Affinity purification of HAv and LAv anti-b 2 GPI
Total IgG from selected sera (sample A and sample B) were isolated by affinity chromatography (MabTrapTM Kit; Amersham, GE Healthcare, Little Chalfont, UK), according to the manufacturer's instructions. LAv and HAv anti-b 2 GPI were isolated by an in-house b 2 GPI affinity column. The column was prepared as described elsewhere (8) by coupling 30 mg of pure human unnicked b 2 GPI (27) to 10 ml of CNBr-activated Sepharose 4B (Sigma-Aldrich, St Louis, MO, USA). The unreacted sites on the matrix were blocked with 0.2 M glycine, and the column was equilibrated with PBS with 0.5 M NaCl and 0.1% Tween 20. Sample A and sample B were applied separately to the b 2 GPI affinity column and circulated for 90 min at 4°C. After extensive washing with 0.05% PBST, LAv anti-b 2 GPI were eluted with 0.5 M NaCl/0.05% PBST and HAv anti-b 2 GPI with 0.1 M glycine/4 M NaCl/0.05% PBST, pH 2.5. Eluates were immediately neutralized, dialysed overnight against PBS pH 7.4 and concentrated (Amicon ultra centrifugal unit; Millipore, Billerica, MA, USA). It should be pointed out that each of these fractions is polyclonal and heterogeneous, still containing specificities of different avidity, but in a specific range (lower or higher) of avidity. For atomic force microscopy (AFM) experiments, anti-b 2 GPI were dialysed against HEPESbuffered saline (10 mM HEPES, 150 mM NaCl), containing 1.5 mM calcium (HBS-Ca 2+ ), pH 7.5, prepared in water for injections (Braun, Melsungen, Germany). Concentrations and activities of recovered anti-b 2 GPI fractions were determined spectrophotometrically (Camspec M501 Single Beam Scanning UV/Visible Spectrophotometer; Camspec Ltd., Cambridge, UK), using the extinction coefficient of 14.0 for the 1% IgG solution and by an in-house anti-b 2 GPI ELISA (25) .
Influence of b 2 GPI density on solid surface on binding of HAv and LAv anti-b 2 GPI
Modified anti-b 2 GPI ELISA was used. Briefly, polystyrene microtiter plates (High binding; Costar, Cambridge, MA, USA) were coated with various amounts of b 2 GPI ranging from 0.3 to 10 ng mm À2 and incubated for 2 h at room temperature. Plates were blocked with 1% BSA (Sigma, St Louis, MO, USA) and after 2 h washed with 0.05% PBST. Same dilutions of LAv anti-b 2 GPI (from sample B) and HAv anti-b 2 GPI (from sample A) ranging from 45 to 453 pM were applied to the wells for 30 min at room temperature. The percentage of anti-b 2 GPI binding was calculated.
Evaluation of monovalent binding of HAv anti-b 2 GPI
Fab fragments of HAv anti-b 2 GPI from sample B were prepared by papain digestion as described (5) . The efficiency of the digestion was confirmed by non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (5) . The elution of Fab fragments from gel slices was done using an Electro-Eluter (Model 422; Bio-Rad Laboratories, Richmond, VA, USA) according to the manufacturer's instructions. For the evaluation of HAv anti-b 2 GPI monovalent binding, different concentrations of high-affinity Fab fragments and HAv anti-b 2 GPI ranging from 20 to 1280 pM were tested by ELISA.
Analysis of antibodies' interaction with b 2 GPI by surface plasmon resonance
Interaction analyses were performed on Biacore T100 instrument (GE Healthcare, Uppsala, Sweden). b 2 GPI was amine coupled to the CM5 Series S sensor chip (GE Healthcare) with N-hydroxysuccinimide and 1-ethyl-3-(3-dimethylpropyl)carbodiimide, using 10 mM acetate, pH 4.0, as a coupling buffer (GE Healthcare). The immobilization level was ;1000 response units (RU). The running buffer was 0.005% PBST, pH 7.4, and the analysis was performed at 25°C at a flow rate of 10 ll min À1 . Seven different concentrations of each anti-b 2 GPI fraction in running buffer were prepared, injected over the sensor surface for a period of 3 min and followed by a 3-min dissociation phase. Regeneration of the sensor surface between sample exposures was done with a short pulse of 10 mM NaOH. Obtained sensorgrams were corrected by double subtracting the signal obtained on a reference surface and the signal of the running buffer. For evaluation of relative binding affinity of polyclonal anti-b 2 GPI, a procedure described by Metzger et al. (28) was used.
Binding of HAv and LAv anti-b 2 GPI to native b 2 GPI in solution
Two dilutions (0.45 and 0.06 nM) of LAv anti-b 2 GPI (from sample B) and HAv anti-b 2 GPI (from sample A) and HCAL were prepared in 0.05% PBST and mixed with purified b 2 GPI (8). The final concentrations of b 2 GPI were 8, 5, 2, 1, 0.5, 0.2, 0.1 and 0 lM. After 2 h incubation, at room temperature, the extent of anti-b 2 GPI binding to native b 2 GPI in solution was determined by anti-b 2 GPI ELISA (25) .
Effect of HAv anti-b 2 GPI on ANX A5 anticoagulant crystal shield on an artificial membrane analysed by atomic force microscopy
The effect of HAv anti-b 2 GPI on incompletely crystallized ANX A5 on SPBs was observed and studied with AFM in a liquid environment using a Nanoscope IIIa-MultiMode AFM (Digital Instruments, Santa Barbara, CA, USA) equipped with the E (15 lm) scanner, as previously described (21) .
Briefly, SPBs composed of 30% (w/w) of La-phosphatidylserine and 70% of L-a-phosphatidylcholine (Sigma-Aldrich) were prepared on mica (21) . When the presence of SPB was confirmed, ANX A5 (10 mg l À1 in HBS-Ca 2+ ) isolated from human placenta (Sigma-Aldrich) was injected into the fluid cell of the AFM. After formation of the ANX A5 crystalline shield incompletely covering the SPB, b 2 GPI (0.15 g l À1 in HBS-Ca 2+ ) and HAv antib 2 GPI from sample A (0.4 g l À1 in HBS-Ca 2+ ) or control antibodies (from serum C, 10 g l À1 in HBS-Ca 2+ ) were added to the ANX A5 solution covering the SPB. The effect of the antigen-antibody pair on incompletely crystallized ANX A5 on SPBs was measured for 60 min.
Results
Influence of b 2 GPI density on solid surface on binding of HAv and LAv anti-b 2 GPI
LAv and HAv anti-b 2 GPI of equal concentrations were applied to decreasing antigen densities immobilized on microtiter plates. It was observed that LAv anti-b 2 GPI were far more dependent of b 2 GPI density than HAv anti-b 2 GPI. On high-density b 2 GPI (10 ng mm À2 ), both fractions exhibited comparable degrees of binding ( Fig. 1, left) , whereas on low-density b 2 GPI, a distinct difference in binding was observed between the two groups. While the binding of HAv anti-b 2 GPI was still effective, though diminished to some degree due to a lower amount of the antigen, the binding of LAv fraction was completely abolished (Fig. 1, right) . To achieve an effective binding of LAv anti-b 2 GPI and HAv anti-b 2 GPI, densities of 2.5 ng mm À2 and 0.6 ng mm À2 of b 2 GPI, respectively, were required, pointing to a greater tendency of LAv anti-b 2 GPI to bivalent binding, feasible above the threshold of the antigen density.
Evaluation of monovalent binding of HAv anti-b 2 GPI
High-affinity Fab fragments exhibited concentration-dependent binding to immobilized b 2 GPI. At low concentrations, the binding of HAv anti-b 2 GPI (bivalent molecules) and high-affinity Fab fragments (monovalent molecules) to b 2 GPI were almost Relevance of anti-b 2 GPI avidity 513 equal (Fig. 2) . With increasing concentrations, the binding of monovalent high-affinity Fab fragments and bivalent HAv antib 2 GPI differed up to 32%. Our results confirmed that considerable amounts of HAv anti-b 2 GPI bound monovalently to the antigen.
Surface plasmon resonance analysis of antibodies' interaction with immobilized b 2 GPI A biosensor analysis was used to observe the binding characteristics of polyclonal LAv and HAv anti-b 2 GPI in real time. Monoclonal anti-b 2 GPI (HCAL) was used to evaluate the stability of a b 2 GPI-coated surface (1000 RU corresponding to 1 ng mm À2 (29)) and to determine the optimal experimental conditions. The reproducibility of responses confirmed the relevance of regeneration protocol to disrupt antibodyantigen interactions without compromising the activity of the latter (data not shown). A healthy donor's IgG (IgG D) represented the negative control.
For biosensor analysis, the amount of active polyclonal anti-b 2 GPI was determined by ELISA. The highest possible concentrations together with 1:1 serial dilutions of active anti-b 2 GPI obtained by several isolations were used: LAv anti-b 2 GPI from sample A and sample B at 156 and 110 nM and HAv anti-b 2 GPI from sample A and sample B at 308 and 122 nM, respectively. The responses of LAv and HAv anti-b 2 GPI were concentration dependent, as shown in Fig. 3 . IgG D did not bind to b 2 GPI, as expected (Fig. 3) . The shapes of interaction curves for LAv and HAv antib 2 GPI (for sample A and sample B) differed noticeably. It is evident from Fig. 4 that sample A contained a more homogeneous population of antibodies in terms of avidity (antibodies of more uniform avidity), whereas sample B contained an extremely heterogeneous population of antibodies where difference in avidity was more pronounced.
The amount of bimolecular b 2 GPI-anti-b 2 GPI complexes was determined by measuring the amplitude of the surface plasmon resonance (SPR) signal 176 s after sample injection. The HAv fraction from sample A (154 nM) gave a signal of 501 RU, while for the LAv fraction (156 nM), a lower signal of 442 RU was determined. For sample B, the same yet more pronounced trend was observed: 759 RU for HAv fraction (122 nM) and 284 RU for LAv fraction (110 nM). Results indicated that the polyclonal HAv anti-b 2 GPI fraction contained a higher amount of antibodies capable of binding to covalently immobilized b 2 GPI at a density of 1 ng mm À2 than LAv fraction. Furthermore, the stability of bimolecular b 2 GPIanti-b 2 GPI complexes was determined by a decrease in the SPR signal 100 s after the outset of the dissociation period (designated as a percentage of dissociation). Dissociation of LAv anti-b 2 GPI, 54.3 6 2.8% (sample A) and 71.9 6 2.4% (sample B) was significantly faster than of HAv anti-b 2 GPI, calculated as 37.8 6 3.1% (sample A) and 28.2 6 3.4% (sample B) suggesting greater stability of bimolecular b 2 GPI-HAv anti-b 2 GPI complexes.
Binding of HAv and LAv anti-b 2 GPI to native b 2 GPI in a solution
To evaluate the binding of LAv and HAv anti-b 2 GPI to b 2 GPI in a solution, inhibition experiments were performed. Both fractions of anti-b 2 GPI and HCAL were tested at two concentrations: one corresponding to a low-positive (0.06 nM) and the other to a high-positive ELISA titer (0.45 nM). Antibody solutions were incubated with various concentrations of b 2 GPI in a solution. Binding of anti-b 2 GPI in an ELISA was inhibited by a concentration-dependent manner by b 2 GPI in a solution. HCAL exhibited an average binding to b 2 GPI in a solution, similar to that reported by Ambrozic et al. (30) . Such a result was expected, considering that HCAL is a chimeric antibody containing murine complementarity determining regions and considerable avidity of murine monoclonals (31) . Results indicate that the binding of HAv anti-b 2 GPI to b 2 GPI in a solution was far more pronounced than of LAv anti-b 2 GPI. The binding of HCAL to b 2 GPI in a solution was higher than the binding of LAv anti-b 2 GPI and lower than the binding of HAv anti-b 2 GPI. A detectable decrease in ELISA signal of HAv anti-b 2 GPI was observed at 0.1 lM of b 2 GPI, regardless of the antibody concentration. HAv antib 2 GPI inhibition of 50% was achieved using physiological concentrations of b 2 GPI; meaning 4 lM at a high and 1.2 lM at a low antibody titer (Fig. 5) . For a notable decrease in ELISA signal of LAv anti-b 2 GPI, 5-10 times higher concentrations of b 2 GPI were required than for HAv anti-b 2 GPI. The latter also exhibited a far steeper b 2 GPI concentrationdependent decrease of ELISA signal than the former. With the highest amount of b 2 GPI (8 lM) and the antigen versus antibody molar ratio 10 5 :1, only 33% inhibition of LAv antib 2 GPI was achieved ( Fig. 5 ).
Influence of HAv anti-b 2 GPI on ANX A5 anticoagulant crystal shield on an artificial membrane
In order to simulate the physiological conditions of the activated cell surface, SPBs from naturally derived phospholipids were prepared on mica (thicknesses of SPBs were 3.6 6 0.4 nm) and ANX A5 was crystallized over SPBs (thicknesses of crystalline ANX A5 layer over SPBs were 2.6 6 0.2 nm) (in detail in ref. (21) ). When b 2 GPI and HAv antib 2 GPI were added to incompletely crystallized ANX A5 on SPB, the growth of b 2 GPI-HAv anti-b 2 GPI complexes (14-16 nm higher than the phospholipid surface) was detected ( Fig. 6) .
HAv anti-b 2 GPI alone did not bind to SPB or ANX A5 and had no effect on ANX A5 crystalline lattice structure. For control antibodies IgG C (isolated from a healthy donor without anti-b 2 GPI), no binding of antibodies to b 2 GPI or effect on crystalline ANX A5 was detected. The order of addition of reagents into the AFM fluid cell to SPBs had no effect on the result.
Discussion
Isolation and characterization of HAv and LAv anti-b 2 GPI
Anti-b 2 GPI are the main pathogenic players in APS. Reports demonstrating the clinical relevance of HAv anti-b 2 GPI prompted us to better characterize binding and functional features of HAv anti-b 2 GPI. Some features, however, may not be evident when dealing with a patient's entire polyclonal anti-b 2 GPI fraction which contains antibodies of heterogeneous avidity. Therefore, we separated the anti-b 2 GPI of each patient (HAv sample A and heterogeneous avidity sample B) by affinity chromatography using gradient elution of increasing ionic strength and obtained fractions containing predominately HAv and fractions containing predominately LAv anti-b 2 GPI.
The evaluation of antigen density dependence and binding characteristics under flow conditions revealed some unique features of HAv and LAv anti-b 2 GPI. The antigen density influenced bindings of both fractions; however, the influence was far less pronounced for HAv anti-b 2 GPI. This indicated that LAv anti-b 2 GPI require bivalent interactions with the antigen, whereas the binding of HAv anti-b 2 GPI to b 2 GPI was predominately monovalent and therefore only slightly influenced by the antigen density, as previously suggested (5) . The latter was also confirmed by only slight differences observed in the binding of bivalent (IgG) and monovalent (Fab) high-affinity anti-b 2 GPI molecules to b 2 GPI immobilized on a microtiter plate. Biosensor analysis, performed at lower antigen density than in the ELISA, further confirmed the distinct influence of antigen density on the binding of LAv antibodies. Despite identical concentrations of antibodies, the HAv anti-b 2 GPI formed a larger amount of bimolecular antibody-antigen complexes than the LAv anti-b 2 GPI, as revealed by the amplitude of the SPR signal ( Fig. 4) . HAv anti-b 2 GPI also formed more stable bimolecular antibody-antigen complexes with b 2 GPI than LAv anti-b 2 GPI. Analysis of SPR sensorgrams showed slower dissociation of b 2 GPI-HAv anti-b 2 GPI than of b 2 GPI-LAv anti-b 2 GPI complexes.
Unexpectedly, the SPR analysis also revealed an interesting difference in the anti-b 2 GPI profiles of the two samples being studied: a homogeneous avidity of sample A anti-b 2 GPI and an extremely heterogeneous avidity of sample B anti-b 2 GPI. Considering the severity of patients' disease manifestations, it was reasonable to assume that patients with homogeneous HAv anti-b 2 GPI profile were more prone to develop severe forms of APS than those with a more heterogeneous profile. We can speculate that patient A (compared with patient B) with predominant HAv anti-b 2 GPI antibodies had a more aggressive thrombophilic serologic profile resulting in catastrophic APS, from which he later succumbed.
Conformational change of native b 2 GPI induced under the influence of HAv anti-b 2 GPI It has been recently reported that b 2 GPI can exist in two conformations: a circular plasma conformation and an active open conformation (31) . According to the authors, only the murine monoclonal antibodies, which have adequate (high) affinity for b 2 GPI's domain I to interrupt the hydrophilic interaction between domains I and V, recognized the circular conformation. The (low affinity) patients' anti-b 2 GPI, however, only recognized the open conformation (31) . On the contrary, our results show that the patient's HAv anti-b 2 GPI contained a considerable amount of antibodies that recognized the circular confirmation since they exhibited moderate affinity towards soluble b 2 GPI. About 50% inhibition of their binding to immobilized b 2 GPI was easily achieved with physiological concentrations of b 2 GPI (32). On the other hand, the binding of LAv anti-b 2 GPI to the antigen in a solution was rather weak, as already reported (33) (34) (35) and indicated their incapacity to interrupt the bond between domains I and V. However, our findings could also indicate that HAv anti-b 2 GPI bound to native epitopes on b 2 GPI, whereas the binding of LAv anti-b 2 GPI depended on epitopes exposed at the surface of the immobilized antigen. Fig. 6 . AFM deflection images and a scheme of the effect of b 2 GPI and HAv antibodies against b 2 GPI (HAv anti-b 2 GPI) on crystalline annexin A5 (ANX A5) on SPBs. (A) Image of mica and crystalline ANX A5 (10 mg l À1 in HBSCa2+) not completely covering the SPB; (B) after 15 min of incubating the ANX A5 solution (10 mg l À1 in HBS-Ca2+) over the SPB crystalline ANX A5 completely covered the SPB. The right lower corner shows 100 3 100 nm 2 ANX A5 crystalline structure where p6 crystal form can be observed; (C) however, if b 2 GPI (0.15 g l À1 in HBS-Ca2+) and HAv anti-b 2 GPI isolated from sample A (0.4 g l À1 in HBS-Ca2+) were added to the ANX A5 (10 mg l À1 in HBS-Ca2+) solution covering the incomplete crystalline ANX A5 layer over the SPB, the complexes of b 2 GPI and HAv anti-b 2 GPI on SPB were measured as well. Antibodies and antigen formed complexes with apparently sufficient affinity to bind to SPB in the presence of crystalline ANX A5. The complexes of b 2 GPI and HAv anti-b 2 GPI bound to exposed mica surface as well; (D) image of further lateral growth of b 2 GPI-HAv anti-b 2 GPI patches on SPB in the presence of incompletely crystallized ANX A5 on SPB is shown; (E) scheme of binding complexes of b 2 GPI and HAv anti-b 2 GPI on mica and to SPB in the presence of incompletely crystallized ANX A5. Impaired formation of ANX A5 anticoagulant crystal shield on an artificial membrane under the influence of HAv anti-b 2 GPI Since Irman et al. (21) reported that anti-b 2 GPI affect only the ANX A5 shield incompletely covering SPBs, the functional features of HAv anti-b 2 GPI were evaluated through their effects on incomplete ANX A5 shield. The effects of HAv anti-b 2 GPI in the presence of b 2 GPI were visualized and evaluated by imaging with AFM. Vertical heights of the ANX A5 crystalline layer and supramolecular assemblies of b 2 GPI on SPBs were in agreement with previous studies (20) (21) (22) (36) (37) (38) (39) .
When b 2 GPI and HAv anti-b 2 GPI were applied to incompletely crystallized ANX A5 on SPBs, the growth of b 2 GPI-HAv anti-b 2 GPI complexes on the exposed phospholipid surfaces was detected. This effect prevented the formation of the anticoagulant ANX A5 shield in vitro. We suggest that HAv anti-b 2 GPI were able to dimerize b 2 GPI and via immune complexation to multimerize the protein. These multimerized b 2 GPI-HAv anti-b 2 GPI complexes had much higher affinity for a phospholipid surface than the antigen alone, were adequately stable (as established above) and were therefore able to compete with ANX A5 for the exposed binding sites on negatively charged phospholipid surfaces. The results were in agreement with the previously suggested secondary pathogenic role of anti-b 2 GPI, where preliminary endothelial damage or deficiency in ANX A5 synthesis or function is required for the development of thrombotic events (21) .
In the present study, HAv anti-b 2 GPI were separated from LAv anti-b 2 GPI and differences regarding their binding characteristics were established. In addition to HAv anti-b 2 GPI's predominant monovalent binding and ability to form stronger complexes with b 2 GPI than LAv anti-b 2 GPI, the former were also shown to recognize and bind b 2 GPI in a solution. In our study, the pathogenic role of HAv anti-b 2 GPI in APSassociated features was demonstrated by their ability to interfere with the formation of the anticoagulant ANX A5 shield. HAv anti-b 2 GPI were suggested to be clinically relevant due to their stronger correlation with thrombotic events in patients. As suggested previously (8) , we continue to demonstrate the clinical importance of HAv anti-b 2 GPI, showing that the homogeneous HAv serum profile of antib 2 GPI present in one of our patients led to catastrophic thrombotic events.
